Core Viewpoint - The company has achieved significant milestones with its drug development and stock market performance, indicating strong investor interest and potential growth opportunities. Group 1: Drug Development - The company announced that its oral PD-L1 inhibitor ABSK043 and the KRAS G12C inhibitor from Elysium, Goretinib, received IND approval in China for a Phase II clinical trial targeting KRAS G12C mutated NSCLC [1] - In March, the company entered into a collaboration agreement with Elysium regarding ABSK043, which is now being evaluated in combination with Goretinib [1] Group 2: Stock Market Performance - The company's stock opened over 6% higher, reaching a historical high of 18.92 HKD, and is currently trading at 18.28 HKD with a trading volume of 11.2474 million HKD [1] - On August 13, the company was included in the MSCI Global Small Cap Index, effective after the market close on August 26 [1] - Allianz SE increased its stake in the company from 4.81% to 5.10%, joining other notable foreign investors such as Eli Lilly Asia, Qiming Venture Partners, and Morgan Stanley [1] - The company repurchased 200,000 shares on August 27 and another 100,000 shares on August 28, totaling 9.545 million shares repurchased for 75.3 million HKD as of June 30, 2025 [1]
和誉-B盘中涨逾6%创新高 公司近期迎多重利好-股票-金融界